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ABSTRACT
We have developed a mathematical framework for describing a bispeciﬁc monoclonal antibody interaction
with two independent membrane-bound targets that are expressed on the same cell surface. The
bispeciﬁc antibody in solution binds either of the two targets ﬁrst, and then cross-links with the second
one while on the cell surface, subject to rate-limiting lateral diffusion step within the lifetime of the
monovalently engaged antibody-antigen complex. At experimental densities, only a small fraction of the
free targets is expected to lie within the reach of the antibody binding sites at any time. Using ordinary
differential equation and Monte Carlo simulation-based models, we validated this approach against an
independently published anti-CD4/CD70 DuetMab experimental data set. As a result of dimensional
reduction, the cell surface reaction is expected to be so rapid that, in agreement with the experimental
data, no monovalently bound bispeciﬁc antibody binary complexes accumulate until cross-linking is
complete. The dissociation of the bispeciﬁc antibody from the ternary cross-linked complex is expected to
be signiﬁcantly slower than that from either of the monovalently bound variants. We estimate that the
effective afﬁnity of the bivalently bound bispeciﬁc antibody is enhanced for about 4 orders of magnitude
over that of the monovalently bound species. This avidity enhancement allows for the highly speciﬁc
binding of anti-CD4/CD70 DuetMab to the cells that are positive for both target antigens over those that
express only one or the other We suggest that the lateral diffusion of target antigens in the cell membrane
also plays a key role in the avidity effect of natural antibodies and other bivalent ligands in their
interactions with their respective cell surface receptors.
Abbreviations:M&S, modeling and simulation; ODE, ordinary differential equation; Kd, dissociation equilibrium con-
stant; ka, association rate constant; kd, dissociation rate constant; mAb, monoclonal antibody; MFI, mean ﬂuores-
cence intensity; EGFR, epidermal growth factor receptor; IGF1R, insulin-like growth factor 1 receptor
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Introduction
Mathematical modeling and simulation (M&S) is frequently
used for testing hypotheses and gaining quantitative insight
into the dynamics of complex systems. This is especially rele-
vant for the understanding and prediction of properties of ther-
apeutic bispeciﬁc monoclonal antibodies (mAbs), of which
many different formats are in development.1 These engineered
proteins do not exist naturally, but are expected to allow
improved drug targeting and efﬁcacy compared with the wild-
type mAbs. As a result, there is an increasing number of bispe-
ciﬁc mAbs entering clinical trials, with targets ranging from
cytokines to membrane-expressed receptors.2-4
While bispeciﬁc mAb interactions with 2 different soluble
targets can be expected to be independent from each other, the
situation is different when both targets are expressed on
the surface of the same cell. In this case, efﬁcient binding can
be observed at antibody concentrations well below the values of
individual dissociation constants (Kd) for either interaction, as
was convincingly demonstrated recently by Mazor et al.5,6 who
studied the reactivity of a series of anti-CD4/CD70 DuetMab
bispeciﬁc mAbs against cells expressing both targets or just one
or the other. Even more, these experimental results suggested
that, at the concentrations tested, the DuetMab fraction bound
to dual-positive cells was always engaging both antigens at the
same time, despite CD4 and CD70 surface density being too
low for both antigens to be simultaneously within the reach of
the antigen-binding sites on the two arms of the mAb.
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No quantitative analysis was given in Mazor et al.5 to
describe and predict how the bispeciﬁc mAb used interacted
with the two cell-surface antigens, which are not known to
interact with each other and are expressed at densities for
which the average distance of »45 nm between the individual
molecules far exceeds the approximately 9 nm reach of the anti-
body antigen-binding arms. Given the growing interest in IgG-
like bispeciﬁc antibodies in the biopharmaceutical industry, as
evidenced by advances in heterodimerization technology and
the various alternative formats being considered (e.g., Genen-
tech “knob-into-holes”,7 kλ-bodies from Novimmune,8 and
others9), we developed a quantitative M&S framework to
address this issue and compared the predictions with the exper-
imental results published by Mazor et al.6 in the expectation
that the principles described can also be extended to more com-
plex cases in future.
We analyze an IgG-like bispeciﬁc mAb that binds ﬁrst either
of the two antigens on the cell surface to form a reversible
monovalently bound binary complex. The remaining free bind-
ing site of the mAb in the binary complex then binds a free sec-
ond target molecule on the cell surface to form a ternary
complex (Fig. 1).
In the ﬁrst step, one of the reactants is in solution and the
other one is on the surface, while in the second step both reac-
tants are surface-bound. We used two alternative approaches to
model the reaction scheme shown in Fig. 1B. The ordinary dif-
ferential equation (ODE) model is based on the well-stirred
assumption. Monte Carlo (MC) simulations are slower, but are
not constrained by well-stirred approximation and explicitly
deﬁne the role for diffusion and Brownian motion. Both models
can be formulated using experimentally measurable parameters
only and do not rely on empirical curve-ﬁtting.
The resulting models can be useful for pharmacokinetic and
pharmacodynamic modeling of novel drug candidates and tar-
gets, as well as understanding bivalent ligand interaction with
two cell membrane receptors in general. We also consider the
implications for monospeciﬁc and bispeciﬁc mAbs binding to
homo- and heterodimeric membrane-bound targets, and con-
sider the advantages and disadvantages of applying a combina-
tion of monospeciﬁc mAbs vs respective bispeciﬁc variants in
the case of cell surface-expressed targets.
Results
Mazor et al.6 analyzed the binding activity of the parent Duet-
Mab that had high afﬁnity for CD4 (Kd D 0.9 nM) and low
afﬁnity for CD70 (Kd D 25 nM) using cells expressing both
antigens at the same time or just one or the other. In agreement
with the experimental data, both ODE and Monte Carlo models
predict higher binding of the DuetMab to dual-positive
CD4C/CD70C and single-positive CD4C/CD70¡ cells than to
the CD4¡/CD70C ones (Fig. 2).
In an effort to improve DuetMab preferential binding to
dual-positive cells, Mazor et al.6 constructed a series of Duet-
Mab variants with progressively attenuated afﬁnities for CD4,
while keeping the binding for CD70 unchanged. Surprisingly,
strong binding of DuetMab variants even at 1 nM concentra-
tions to CD4C/CD70C dual-positive cells was virtually unaf-
fected, while all but non-speciﬁc binding was eliminated on
single-positive CD4C/CD70¡ and CD4¡/CD70C cells. We ﬁnd
that both ODE and Monte Carlo models adequately capture
these experimental ﬁndings, when rapid ﬁrst-order dissociation
of monovalently bound DuetMab species according to their
dissociation rate constant from the single-positive CD4C/
CD70¡ and CD4¡/CD70C cells is taken into account, as shown
on Figs. 3(A, B and C).
We therefore conclude that both ODE and MC approaches are
in agreement with the experimental data described by Mazor
et al.,6 as well as with each other and hence both approaches can
be used to gain further insight into the DuetMab-type bispeciﬁc
antibody interactions with cell surface targets.
Both ODE and MC models suggest that steady-state equilib-
rium is only achieved during the one hour experimental incuba-
tion step at DuetMab concentrations above 1 nM. Progressively
longer incubation times at lower concentrations would increase
the amount of bound antibody to an extent, as shown in Fig. 4.
While very long incubation times are not experimentally feasible
for the labeling of live cells at low temperatures, this would be rel-
evant in a therapeutic setting, given the long in vivo half-life of
antibodies. It should, however, be noted that in this case target
internalization kinetics (suppressed in the cell labeling experi-
ment due to the low temperature and omitted in the model)
would also need to be taken into account.
Figure 1. The anti-CD4/CD70 DuetMab described by Mazor et al.5,6 and our proposed reaction scheme. (A) A DuetMab is monovalent for either of the antigens and shares
the overall structure with natural IgG. Appropriate pairing of the 2 different pairs of heavy and light chains is achieved through proprietary guiding mutations. (B) Duet-
Mab in solution binds either of the 2 cell surface antigens to form a surface-bound binary complex (reactions 1 and 2), which then cross-links with the second target to
form a ternary complex (reactions 3 and 4). Surface-bound species are underlined. Reactions involving surface-bound species only are shaded.
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We next used ODE and Monte Carlo models (where feasi-
ble) to consider the relative surface concentrations of binary
and ternary complexes of the DuetMab-like bispeciﬁc mAb as a
function of an extended antibody concentration range in
steady-state equilibrium conditions. The modeling results for
three different DuetMabs are shown in Fig. 5 in mean ﬂuores-
cence intensity (MFI) cell surface concentration units for easier
comparison purposes: the parent molecule, the Vk(R95A) vari-
ant where afﬁnities for both CD4 and CD70 are nearly equal
and the weakest CD4-binding Vk(R94A)CVhY99A variant. In
this case, the dissociation step applied in Fig. 2–3 has been
omitted to show the predicted steady-state equilibrium surface
concentration values that would be relevant in a therapeutic
setting, again in MFI units for ease of comparison. In the case
of dual-positive CD4C/CD70C cells, as the DuetMab concentra-
tion increases to about 50 nM, target cross-linking is expected
to take place ﬁrst, with monovalently CD70-bound antibody
species starting to accumulate only after all available CD4 has
been sequestered into ternary complexes. This is in agreement
with the experimental observations by Mazor et al.,5,6 who did
not ﬁnd any monovalently bound DuetMab on the dual-posi-
tive CD4C/CD70C cells. At antibody concentrations of »1 mM
(approximate maximum plasma concentration after therapeuti-
cally relevant 10 mg/kg dose) and higher, the reaction between
a free surface target and a volume phase bispeciﬁc antibody
increasingly outcompetes target cross-linking on the cell sur-
face. This is expected to result in the accumulation of binary
complexes at the expense of the ternary ones, but, due to the
antibody concentrations required, is unlikely to be experimen-
tally relevant. In the case of single-positive cells, the binding of
the DuetMab is expected to follow simple monovalent mass
action kinetics according to their respective Kd values for either
antigen, as shown in Figs. 5B-C.
Of special interest here are the DuetMab equilibrium bind-
ing curves to the single- and dual-positive cells, where the latter
allows both antigen-binding arms of the antibody to interact
with cell-surface antigens. Bivalent attachment of the bispeciﬁc
antibody to the targets adds about 4 orders of magnitude to the
effective binding potency of the molecule relative to the mono-
valently bound one.
Finally, using the ODE model we also analyzed the dissocia-
tion kinetics of bivalently bound DuetMab variants from dual-
positive CD4C/CD70C cells, starting from the saturating cross-
linked ternary surface complex with no antibody in solution.
Unsurprisingly, while the dissociation reaction is faster for the
more weakly binding variants, it happens very slowly compared
with the expected monovalent dissociation curves, and it does
not follow ﬁrst order kinetics, getting progressively slower as
the bound fraction decreases (Fig. 6).
The expected dissociation half-lives are very long and exceed
t1=240h even for the weakest-binding VkR94ACVhD97A vari-
ant, which from the respective single-positive cells would be
expected to dissociate within minutes according to ﬁrst-order
kinetics (Table 1).
Discussion
Using the simple reaction scheme outlined on Fig. 1B, and only
relying on experimentally measurable parameters with well-
deﬁned biochemical/biophysical meaning, we have described
the data reported by Mazor et al.,6 who, in demanding and
complex experiments, studied the binding of a series of anti-
CD4/CD70 DuetMabs to three different types of cells in vitro.
The key aspect of our approach, irrespective of whether ODE
or Monte Carlo methods were used, is the appreciation that the
cross-linking reaction is likely to take place between two sur-
face-bound molecules with reduced degrees of freedom that
also are subject to lateral diffusion/Brownian motion in cell
membrane.
The latter is characterized by a diffusion constant D, which
typically lies for cell surface proteins in the range of 10¡9
to 10¡11 cm2/s,10 about 2–4 orders of magnitude lower than
D D 4£10¡7 cm2/s that has been measured for IgG in solution
by Kihara et al.11 The average two-dimensional mobility of cell
membrane proteins can be estimated according to Einstein12
x2 D 2Dt (8)
where x2 denotes mean square distance of displacement for
particles undergoing Brownian motion, D is the diffusion coef-
ﬁcient and t is time. At D D 10¡10 cm2/s, it will take » 0.5 sec-
onds for individual receptors to move on average »100 nm
from their initial position. This period of time is short com-
pared with the half-lives of typical antibody-antigen complexes
that can reach into hours, and conﬁrms that target cross-link-
ing by a bispeciﬁc mAb is kinetically possible even when the
average distances on the surface exceed the reach of the anti-
gen-binding arms of the mAb. Combined with dimensional
reduction, this means that the cross-linking reaction is very
fast, ensuring that any monovalently bound bispeciﬁc antibody
molecule quickly binds the other target too, if available.
Figure 2. The experimentally measured and predicted binding of the parent
DuetMab in ﬂow cytometry assay. Filled circles, squares and triangles are experi-
mental data measured by Mazor et al.6 for CD4C/CD70C, CD4C/CD70¡ and CD4¡/
CD70C cells, respectively. Empty symbols represent Monte Carlo simulation results
and the lines are the ODE simulation results for the same cell types, respectively.
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Figure 4. The predicted effect of time on the ﬂow cytometric binding of the parent DuetMab to CD4C/CD70C dual-positive cells. (A) One-hour incubation with the anti-
body. Solid lines from left to right are ODE simulations at 100 nM, 10 nM, 1 nM, 0.1 nM and 0.01 nM constant DuetMab concentrations. Dotted lines denote respective
Monte Carlo simulations. (B) Extended incubation time is predicted to increase DuetMab binding at lower concentrations. Black solid, dashed, dot-dashed, dotted and
gray solid lines denote the ﬂow cytometric binding curve simulations for 1 h, 10 h, 100 h, 1000 h and 10000 h incubation times.
Figure 3. Experimental and predicted ﬂow cytometric cell binding curves for the parent and modiﬁed DuetMabs. Black squares, brown triangles pointing up, blue circles,
green triangles pointing down, purple diamonds and yellow circles denote parent DuetMab and the anti-CD4 afﬁnity attenuated variants VkY92A, VkY91A, VkR95A,
VkR95ACVhD97A and VkR94ACVhD97A. Filled symbols denote the experimental data measured by Mazor et al.,6 and empty symbols Monte Carlo simulation results.
Lines denote ODE simulation results in the same order. A) dual-positive CD4C/CD70C cells, B) single-positive CD4C/CD70¡ cells and C) single-positive CD4¡/CD70C cells.
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Effectively, the activity of a binding site depends on the state of
the second site in the antibody molecule, i.e., they are not inde-
pendent even if they are not expected to be directly interacting
at all. As a result, no monovalently bound DuetMab was found
by Mazor et al.,5,6 an observation similar to that made by Gavu-
tis et al.13 for interferon binding to its heterodimeric receptor.
In addition, even if a dissociation event does take place in a ter-
nary complex, the species are still so close that the bond is likely
to reform or another one to come by, depending on the relative
speed of surface and volume reactions. Kinetically, this mani-
fests as enhanced binding of an antibody through slower disso-
ciation where half-lives are in hundreds of hours,14 which is
commonly referred to as the avidity effect. We have shown
here how the avidity effect can be accounted even when the
epitopes are on freely moving non-interacting target molecules.
It is sufﬁcient for the targets to be anchored on the same cell
membrane, and the epitopes do not necessarily need to reside
on the same molecule or even on proteins within a stable target
complex. We suggest that the same principle also applies to
natural antibodies, of which the VkR95A variant DuetMab
with its equal afﬁnities for either target is a close analog on
dual-positive cells.
A mechanistic model is usually an abstraction which reﬂects
the modellers’ interpretation of the information available for the
system of interest and the kind of insight sought. To date, two
approaches that aim to describe bispeciﬁc antibody interaction
with two targets expressed on cell surface have been reported.
First, Burke15 developed a more sophisticated model that also
incorporates the targets’ turnover and clearance pathways both for
the free and bound versions of the drug. As for the drug-target
interactions, those taking place between surface-bound species are
deﬁned though as if they were in solution, but with thousand-fold
lower dissociation rate constants and 4-fold increased association
rate constants. While superﬁcially similar to the slower dissocia-
tion we predict for the cross-linked DuetMab, this approach con-
tains an interesting paradox whereby the rate of the cross-linking
reaction between membrane-bound species of deﬁned surface
concentration, say on a single cell, depends in the size of the vol-
ume in which this cell is suspended. Second, van Steeg et al.16 have
adapted the avidity models developed by Kaufman and Jain17 and
M€uller et al.,18 for describing mAb binding in ELISA and BIAcore
assays, respectively, to achieve good agreement between the model
and data for mono- and -bispeciﬁc mAb binding to cells express-
ing EGFR and IGF1R targets. These ﬁxed target position models
Figure 5. Predicted steady-state cell surface concentration of DuetMab in MFI units. Black: parent DuetMab, green: Vk(R95A) variant and yellow: Vk(R94A)CVhY99A vari-
ant. ODE predictions (10000 h simulated incubation time), solid lines: total antibody, dashed lines: cross-linked antibodies, dash-dot: CD4-bound antibody, dotted lines:
CD70-bound antibody. Monte Carlo simulation results shown at DuetMab>10 nM (where steady state was achieved at 1h or less). Circles: total antibody, squares: cross-
linked antibodies, diamonds: CD4-bound antibody, pentagrams: CD70-bound antibody. (A) Dual-positive CD4C/CD70C cells, (B) single-positive CD4C/CD70¡ cells, (C) sin-
gle-positive CD4¡/CD70C cells.
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calculate the fraction of any 2 receptors within the reach of the 2
binding sites of a mAb, deﬁned as 49 nm in ref.16, 8.7 nm in ref.17
and 11 nm in ref.18 At receptor densities in excess of hundreds of
thousands of molecules per cell, most of these can be calculated to
lie within cross-linking distance of a mAb irrespective of the access
radius value used, but, on H358 cells expressing 38260 copies
EGFR and 23100 copies of IGF1R per cell,16 this fraction rises
from 1% to around 30% when the access radius value is increased
from 8.7 nm to 49 nm. No direct experimental data is available for
EGFR and IGF1R, but in the case of cells expressing around 50000
copies of CD4 and CD70 each, all surface bound CD4/CD70-bis-
peciﬁc DuetMab antibody was found to be bivalently attached in
saturating conditions,5,6 despite the average 49 nm distance
between the receptors. Within the paradigm of the diffusion
model, the higher effective antibody access radius values used in
the ﬁxed position model16 can be interpreted as accommodating
the effect of the target lateral movement, while the empirically
assigned volume of reaction Vr and surface association reaction
rate constant adjustment parameter Ceff accommodate the two-
dimensional surface reaction kinetics.
Our model has been developed with DuetMab-type bis-
peciﬁc mAbs that bind 2 different non-interacting targets in
mind. Should the targets homo- and heterodimerize, as
described by Mazor et al.5 for an anti-EGFR/HER2 Duet-
Mab, the situation is more complex. If both epitopes on a
heterodimer happen to be optimally placed, a target hetero-
dimer might bivalently bind one DuetMab through both
antigen-binding arms at the same time. Alternatively, if that
is not possible for steric reasons or the rotation of the anti-
gen-binding arms around the mAb hinge region is hin-
dered, hetero-oligomerization is conceivable whereby
DuetMab molecules alternate with target molecules in
chain-like linear structures as discussed and modeled by
Shea et al.19 Without prior knowledge of the location, the
relative orientation of the epitopes and detailed structural
information about the antibody-antigen complex, it will be
difﬁcult to decide which form of cross-linking will prevail.
From the experimental point of view, any oligomeric anti-
body-antigen complexes could be detectable through single-
molecule ﬂuorescence microscopy.20 Therefore, an appropri-
ate model of the formation of dimers or oligomers can be
constructed and used in conjunction with the binding
framework proposed in this model.
In the study reported here, we obtained similar results
both by ODE and Monte Carlo modeling in conditions
where both were applicable, but the two approaches are
complementary and not identical. ODE simulations are
much faster, and hence the only feasible approach for PK
modeling, but they also assume the well-mixed approxima-
tion in the volume and on the surface. There is no such limi-
tation for Monte Carlo simulations, and, albeit at heavy
computational price, local concentration gradients or com-
plex geometries can explicitly be taken into account. Alterna-
tively, partial differential equation models should be
applicable too. Likewise, while the size of the molecules is
not explicitly deﬁned in the ODE approach, this is essential
for the Monte Carlo simulations within a MCell3 environ-
ment when chemical reactions are only allowed between
molecules within reaction distance, here deﬁned as the sum
of respective hydrodynamic radiuses. On a separate note, the
height of the cuboid volume with just 10-fold molar excess
of the DuetMab in Monte Carlo models reached well beyond
the distances encountered between neighboring cells in solid
tissues, suggesting that local gradients may easily develop in
such conﬁned environments, i.e., well-stirred approximations
might not be appropriate. These local gradients would be
expected to be attenuated in vivo by the interstitial ﬂuid ﬂow
that would replenish the antibody lost from the volume
phase. The bulk ﬂow, if present, effectively increases the
Figure 6. ODE-predicted time course in surface concentration MFI units for the dis-
sociation of parent DuetMab (black) and the anti-CD4 afﬁnity attenuated variants
VkY92A (brown), VkY91A (blue), VkR95A (green), VkR95ACVhD97A (purple) and
VkR94ACVhY99A (yellow) from stoichiometrically cross-linked targets on the dual-
positive CD4C/CD70C cells.
Table 1. Kinetic constants used for modeling that are taken from Mazor et al.6 or derived.
CD4 CD70
DuetMab k1£105 1/(M s) k¡1£10¡3 1/s t¡11=2 s 1k¡4£10¡3 1/s k2 £105 1/M s) k¡2£10¡3 1/s t1=2s k3£1013 dm2/(mol s)
parent 2.8 0.26 2665 0.19 2.0 4.9 141 2.4
VkY92A 2.0 1.9 365 1.9 2.0 4.9 141 2.4
VkY91A 2.8 4.7 147 3.3 2.0 4.9 141 2.4
VkR95A 5.4 23 30 8.5 2.0 4.9 141 2.4
VkR95ACVhD97A 5.6 35 20 12.5 2.0 4.9 141 2.4
VkR94ACVhY99A 5.2 36 19 13.8 2.0 4.9 141 2.4
1Calculated according to Equation 10.
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volume available beyond the immediate thickness of the
interstitial ﬂuid layer the cell is exposed to.
Our model, though mechanistic, is an abstraction. The
cell is presented as a sphere of 10 mm diameter that car-
ries on its surface randomly placed non-interacting CD4
and CD70 target molecules. Both targets are subject to lat-
eral Brownian motion deﬁned by the diffusion coefﬁcient
assumed to be uniform across the entire surface of the
cell. We appreciate that the 2D association rate constant
estimated from the CD2-CD58 interaction that we used in
the Monte Carlo model may itself be a composite parame-
ter with fractional components both from diffusion and
intrinsic chemical reaction steps. It was measured in a sys-
tem where one of the reactants was embedded onto an
artiﬁcial membrane where the lateral diffusion coefﬁcients
tend to be higher, i.e., the relative contribution of chemical
reaction may be higher than when both reactants are
linked to a genuine plasma membrane. Recently, Zheng
et al.21 have noted an apparent increase in afﬁnity of an
EGFR/c-Met bispeciﬁc mAb for the second target that fol-
lows the binding of the ﬁrst one, which in the diffusion
model is accounted for through reduction in dimensional-
ity of the surface association reaction, and hence the bind-
ing free energies in these two environments are not
necessarily identical. The rate constants we used to model
reactions taking place at 4C were measured at 25C, and
are likely to be overestimates as both antibody-antigen
association and dissociation rate constants decrease with
temperature, as shown by Johnstone.22 Finally, our model
does not include target-antibody complex internalization
since, at the low incubation temperatures used by Mazor
et al., this process is expected to be negligible. At physio-
logical temperatures, the half-life of receptor-antibody
complexes can vary from minutes to hours23,24 and, being
signiﬁcantly faster than dissociation from the surface-
bound state, as shown on Fig. 6, would need to be
included separately in the kinetic scheme. Despite these
limitations, the surface diffusion model described can be
experimentally veriﬁed and amended, when necessary,
because it only uses experimentally measurable parameters
with well-deﬁned meaning. Not all parameters used in the
model affect the results to the same extent. The BIAcore-
measured rate constants are experimental values that
describe the association and dissociation kinetics of mAbs,
and are essential for the binding curve shown on Fig. 3A
as at low DuetMab concentrations the level of binding
appears kinetically limited. The 1–3 fold microscopic
reversibility correction from Equations 8–10 made no dis-
cernible difference to the ODE simulation results, but was
applied for the correctness, and any future adjustments, if
necessary. Likewise, the two-dimensional chemical reaction
step rate constant value for the Monte Carlo model is of
limited consequence in the current model as long as it
exceeds the rate of the diffusion step. The estimated value
was implemented as it was required by the modeling envi-
ronment. The diffusion-limited association rate constant
value used in the ODE model for the surface-bound reac-
tants accounts for the observed formation of cross-linked
target species on double-positive target cells.
Mazor et al. demonstrated that a DuetMab,5,6 an IgG-like
bispeciﬁc antibody that is monovalent for either antigen, can be
engineered to be highly selective for the targeting of cell popu-
lations in complex mixtures according to the signature combi-
nations of two surface-bound antigens. With the models
described and made available here, we are adding in silico tools
to analyze situations where the antibody afﬁnities, receptor
expression levels or accessibility can vary from one therapeutic
target to another to further accelerate to process of drug discov-
ery. For example, in the case of the recently Food and Drug
Administration-approved combination therapy of cancer with
two anti-CTLA4 and anti-PD1checkpoint inhibitor mAbs
described by Mahoney et al.,25 the targets can be expressed on
T cells found in blood, metastases or vascularized tumors,
which all exhibit drastically different accessibility to antibody
therapeutics, as summarized and quantitatively analyzed by
Wittrup et al.26 Alternatively, if it is desirable to engage the tar-
gets also on single-positive cells, a combination of monospeciﬁc
mAbs may be more appropriate since the avidity boosted bind-
ing to dual-positive cells would be lost on the target fraction
where cross-linking is not possible, unless compensated by sub-
stantially improved monovalent binding afﬁnity, which will
take time and effort to develop.
In summary, we hope that the model presented here will be
useful for accelerating the pace of drug discovery in the bio-
pharmaceutical industry, and also provide a framework for the
quantitative description of bivalent soluble ligand interaction
with two different membrane-bound targets in general in sys-
tems immunology.
Materials and methods
Experimental bispeciﬁc mAb data
MFI data for DuetMab binding to target-expressing cells were
all obtained from the paper by Mazor et al.6 using PlotDigitizer
2.6.8.27 Brieﬂy, Mazor et al.6 incubated human T cells prepared
from peripheral blood lymphocytes with a series of DuetMabs
at desired concentrations for 1 h at 4C, washed twice and
stained for the bound antibody with a secondary ﬂuorescently-
labeled reagent for 45 min at 4C. This was followed by two
ﬁnal washes and ﬂow cytometric analysis for the bound IgG.
The MFI value measured in ﬂow cytometry is expected to be
proportional to the number of cell-bound DuetMab molecules.
We used a conversion factor of 1.18 bound DuetMab mole-
cules/MFI s assuming that, at 16 and 64 nM parent DuetMab
concentrations, its binding to CD4C/CD70- cells is saturating
(Kd D 0.9 nM). CD4 and CD70 expression levels on all three
cell types were obtained from Mazor et al.6
Kinetic scheme for the DuetMab interaction with
two different targets expressed on the surface of the same
cell
CD4 and CD70 are not known to have any binding afﬁnity for
each other, hence random initial distribution and no heterodi-
meric targets on the cell surface are assumed. Given that a tri-
molecular reaction between a solution-phase DuetMab and two
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cell membrane targets is extremely unlikely, we adopt a sequen-
tial mechanism shown in Fig. 1.
We use and compare 2 approaches for mathematical
description of this kinetic scheme: an ODE model and a
numerical Monte Carlo model.
ODE model
The following system of two algebraic equations and three
ODEs describes the reaction scheme outlined in Fig. 2 in condi-
tions where the antibody concentration in solution is constant.
½T1sD ½T1TOTs¡ ½AT1s¡ ½AT1T2s
and
½T2sD ½T2TOTs¡ ½AT2s¡ ½AT1T2s (1)
d½AT1s
dt
D k1½A½T1s¡ k¡ 1½AT1s¡ k3½AT1s½T2s
C k¡ 3½AT1T2s (2)
d½AT2s
dt
D k2½A½T2s¡ k¡ 2½AT2s¡ k4½AT2s½T1s
C k¡ 4½AT1T2s (3)
d½AT1T2s
dt
D k3½AT1s½T2s¡ k¡ 3½AT1T2sC k4½AT2s½T1s
¡ k¡ 4½AT1T2s (4)
In Equations 1–4 [A] denotes DuetMab molar concentration
(M) in solution. The rest are cell surface-bound species in
mol/dm2 units and marked with subscript s. T1 and T2 are free
targets (CD4 and CD70, respectively), AT1 and AT2 are Duet-
Mab complexes with one or the other target and AT1T2 is the
ternary complex between two different targets cross-linked by
one DuetMab molecule. Association rate constants k1 and k2
for reactions between a volume and a surface molecule are in
1/(M s) units, while k3 and k4 for reactions between two surface
molecules are in dm2/(mol s) units. Dissociation rate constants
k-1, k-2, k-3 and k-4 are all in 1/s units.
The initial conditions at t D 0 are deﬁned as
½T10sD ½T1TOTs; ½T20sD ½T2TOTs;
½AT10sD ½AT20sD ½AT1T20sD 0 (5)
where ½T1TOTs and½T2TOTs correspond to the total concentra-
tions of the surface targets assuming uniform distribution on
the surface of a 10 mm diameter spherical cell. Equations 1–4
were implemented using the ode45 function in Matlab R2015b
(The MathWorks Inc., Natick, MA, USA) and in volume con-
centration terms in Simbiology v5.2 (The MathWorks Inc.,
Natick, MA, USA) (Supplementary Data).
Monte carlo (MC) simulation
Simulations were performed using MCell3 (Pittsburgh University
Biological Supercomputing Center, USA),28-31 which is a
computational biology application for Monte Carlo simulation of
biological processes involving diffusion and chemical reactions. A
virtual reaction vessel in the shape of a cuboid with square bottom
surface area of 0.1 mm2 and variable height was deﬁned in the
MCell3 plug-in running in Blender 2.74.32 The bottom of the
cuboid was seeded with the targets T1 and T2 for CD4 and CD70 at
appropriate density for the cell type modeled assuming a sphere of
10mmdiameter (26 and 29 targets for CD4 and CD70 in dual-pos-
itive cells and 21 and 16, respectively, in single-positive cells). The
height of the cuboid was adjusted to accommodate 605 randomly
placed volume phase DuetMabmolecules at the desired concentra-
tion at tD0 to keep themaximum reduction to volume phase Duet-
Mab particles number below 10% (Table S1). 0.1–100ms time steps
and 3 parallel runs were used to simulate the chemical and diffu-
sion processes on a HP Elitebook 8570 w. The rate and diffusion
constant values are listed in Table 2.
Rate constant values
Volume phase rate constants k1, k-1, k2 and k-2 for DuetMab
interaction with CD4 or CD70 were obtained from the article
by Mazor et al.,6 who measured them in vitro using surface
plasmon resonance. No experimental data is available for an
anti-CD4/CD70 DuetMab binding to its respective antigens
when both reactants are surface-bound for the values of k3, k-3,
k4 and k-4. However, k1 and k2 are close to each other for all
DuetMabs studied and within the range that is typical for anti-
body-antigen interactions of 105-106 1/(M s),33 which is consid-
ered to be diffusion-dominated in solution.34 Given that
protein diffusion coefﬁcients in cell membrane are 3–4 orders
of magnitude smaller than for IgG in solution (Table 2), we
postulate that association reaction constants k3 and k4 are equal
and diffusion-dominated also on the cell surface.
According to Torney and McConnell35 and Goldstein,36 the
two-dimensional diffusion-limited association reaction con-
stant kon expressed per molecule is proportional to the sum D
of the reactants’ surface diffusion coefﬁcient values
konD 4D (6)
A number of surface diffusion coefﬁcient values have been
measured for CD4, as listed under Table 2, of which we adopt
the median at » 5£10¡10 cm2/s. No such value is available for
CD70, but, given that it has a single 21–22 amino acid long
Table 2. Target-related parameters. Receptor numbers are from Mazor et al.6
CD4 CD70
Parameter Per cell Per cuboid Per cell Per cuboid
Receptors on CD4C/CD70C cells 82000 26 92000 29
Receptors on CD4C/CD70- cells 68000 22 0 0
Receptors on CD4¡/CD70C cells 0 0 55000 17
1Diffusion coefﬁcient D, cm2/s 5£10¡10 5£10¡10
1CD4 subpopulations of different mobility, characterized by DD1.14£10¡8 cm2/s,
D D 2.34£10¡10 cm2/s and D D 3.31£10¡11 cm2/s were measured by Zhan
et al.,40 D D 5£10¡10 cm2/s according to Pal et al.,41 DD (1.87–20.9)£10¡10 cm2/
s and D D 1.35£10¡10 cm2/s according to Rawat et al.,43 DD5£10¡9 cm2/s
according to Baker et al.43 and D D 2.7£10¡10 cm2/s according to Finnegan
et al.44 mAb solution diffusion coefﬁcient D D 4£10¡7 cm2/s has been reported
by Saltzman.45
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a-helical transmembrane domain similar to that of CD4, we
assume that their diffusion coefﬁcients are similar. If so, the dif-
fusion-limited 2D surface association reaction rate constant in
dm2/mole/s units for the ODE-based model is deﬁned as
k3D k4D 2:4£1013dm2 6 mol sð Þ (7)
According to the principle of general microscopic reversibil-
ity,37 the rate constants for the reaction scheme given on Fig. 2
are related according to Equation 8
k1k¡ 2k3k¡ 4D k¡ 1k2k¡ 3k4 (8)
With the volume reaction rate constants k1, k¡1, k2 and k¡2
measured independently and k3 D k4, this allows the relation of
the surface dissociation constants k¡3 and k¡4 to the volume
reaction constants k1, k¡1, k2 and k¡2
k¡ 4
k¡ 3
D k¡ 1k2
k1k¡ 2
(9)
The dissociation constant for a reaction taking place on the sur-
face does not need to be identical to that taking place in solu-
tion, but can be expected to be related, and the absolute values
in surface and volume concentration conditions for interferon
dissociation from its receptor were only 3-fold different when
measured by Gavutis et al.13 This effect is relatively small and
we hence assume k¡ 3D k¡ 2 for the DuetMab invariant inter-
action with CD70. If so, the surface dissociation rate constant
k¡ 4 for CD4 can be found from its volume dissociation rate
constant value k¡ 1 according to Equation 10. It should be
noted that the correction factor k2/k1 only varies from 0.9 to
2.5, and the choice between assuming either k¡2 D k¡3 or
k¡1 D k¡4 would not affect the simulation results.
k¡ 4D k¡ 1 k2k1 (10)
The MCell Monte Carlo model requires a distinct surface
2D chemical reaction association rate constant value in addi-
tion to the reactants’ surface diffusion coefﬁcients. We use
0.7 mm2/(molecule s) (equivalent to 4.2£1013 dm2/(mols)
that we calculated from the Kd6 molcules/mm2 surface disso-
ciation equilibrium constant and the dissociation rate constant
koff D 5 1/s measured for the interaction between membrane-
bound forms of CD2 and CD58 by Zhu et al.38 and van der
Merwe et al.,39 respectively. In solution, this protein-protein
interaction displays a typical antibody-antigen association rate
constant kon D 2£105 1/(M s).39
DuetMab binding to single-positive cells is monovalent, and
there are no differences between the MFI values for variants
with Kd > 25 nM. This suggests that these surface-bound Duet-
Mabs, with dissociation half-lives in the minute range or less
(Table 1), are lost during the ﬁnal cell washing steps before
ﬂow cytometry. We therefore corrected the model estimates
for DuetMabs bound to single-positive CD4C/CD70¡ and
CD4¡/CD70C cells shown on Figs. 2 and 3 according to the
ﬁrst-order exponential decay function (11) using rate constants
k¡1 and k¡2 for the appropriate DuetMab variant from Table 1.
½AT1D ½AT1ce¡ k¡ 1t ½AT2D ½AT2ce¡ k¡ 2t (11)
where ½AT1c and ½AT2c are the complex concentration value
calculated for one-hour and koff is the dissociation rate constant
k¡1 or k¡2 for the relevant DuetMab-antigen binary complex.
We assume t D 240 s (approximate time required for two spin-
resuspend cycles and rapid ﬂow cytometric analysis). We do
not attempt to quantify in our model the residual experimental
non-speciﬁc binding of low afﬁnity DuetMabs at higher anti-
body concentrations, which appears to reach »15% of the total
on single-positive cells.
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